Though a promising drug failed in clinical trials last year, data from the research provides critical new insights into celiac disease. When patients are exposed to gluten, they show an immune reaction within two hours, more quickly than previously believed. Even the symptoms are different from what many expect. Robert Anderson, MD, PhD, a former lead researcher on Nexvax2, says this is a wakeup call that drug research may be testing patients the wrong way.
Most patients predicted that their worst symptoms when exposed to gluten would be classic lower digestive problems like diarrhea, bloating and cramps. However, none of these occurred during the acute immune responses observed by Anderson’s team. Instead, patients experienced nausea and vomiting. Anderson describes them as, “acute food poisoning symptoms that are early in onset,” and relatively severe.
“For all the years that we’ve known about celiac disease, persons have told us that they had these acute reactions, but many experts in the field dismissed them as being just in the person’s mind,” says Anderson. “Here we are now, a hundred years after celiac disease was discovered, suddenly discovering, yes, the patients were right.”
“For all the years that we’ve known about celiac disease, persons have told us that they had these acute reactions, but many experts in the field dismissed them as being just in the person’s mind,” says Anderson. “Here we are now, a hundred years after celiac disease was discovered, suddenly discovering, yes, the patients were right.”
The celiac immune response involves t-cells, attack cells armed to target gluten. Specialized t-cells take time to activate. So conventional wisdom cast doubt on any symptoms appearing so quickly. However, the Nexvax2 research found evidence of immediate t-cell activity. In 92 percent of celiac patients tested, a protein, interleukin-2, spiked in the blood one hour after they ate gluten.